UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
114,46 $
arrow_downward
−0,87%(−1,01) 1 p
16. okt, 16:00:00 GMT −4 · USD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse UCBJY põhistatistika genereerimine…
Ava
114,95 $
Kõrge
115,28 $
Madal
114,23 $
Turu kapit.
39,39 mld
Keskm. maht
53,31 tuh
Maht
70,57 tuh
52 näd kõrgeim
168,76 $
52 näd madalaim
110,55 $
Beeta
0,57
Käibivad aktsiad
389,01 mln
Töötajate arv
9 tuh
Ava
114,95 $
Kõrge
115,28 $
Madal
114,23 $
Turu kapit.
39,39 mld
Keskm. maht
53,31 tuh
Maht
70,57 tuh
52 näd kõrgeim
168,76 $
52 näd madalaim
110,55 $
Beeta
0,57
Käibivad aktsiad
389,01 mln
Töötajate arv
9 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
ad-hoc-news.de
·
2 tunni eest
UCB launches Wear It Out: what it means for UCB stock
ad-hoc-news.de
·
1 päeva eest
UCB revises Bimzelx potential above EUR 7 billion: UCB stock sits 30.28 percent below its high
ad-hoc-news.de
·
2 päeva eest
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profiil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Teave üksuse UCB Unsponsored Belgium ADR kohta
TegevjuhtJean-Christophe Tellier
Töötajad9 tuh
Asutatud18. jaan 1928
Peakontorid-
Sektor-
Veebisaitucb.com